HCV-related liver disease is a leading cause of mortality among HIV-infected individuals in the U.S. Current therapy for HCV infection has limited efficacy, but the first HCV protease inhibitors were recently approved by the FDA and have substantially improved treatment outcomes. Many HCV-infected individuals, however, are not aware that they are infected. Further, as a result of limited treatment uptake and high rates of loss to follow- up, few HIV/HCV co-infected patients ever initiate HCV therapy. Recognizing the public health challenge represented by HCV, the Institute of Medicine and American Association for the Study of Liver Diseases have called for studies to identify the best strategies for HCV screening and care delivery. We propose to build a mathematical model of HIV/HCV co-infection to generate urgently-needed evidence that will inform screening and treatment guidelines and improve patient outcomes. The three specific aims are: 1. To develop and validate a Monte Carlo simulation model of HIV/HCV co-infection that includes HCV and HIV screening, linkage to and retention in care, and treatment. 2. To use the model to conduct and disseminate a series of analyses that will develop the evidence needed to inform clinical guidelines for identifying and managing HIV/HCV co-infection in the era of directly acting antiviral therapies against HCV. 3. To conduct policy analyses that will develop priorities for improving access to HCV treatment and project the budgetary impact of widely-available directly acting therapies against HCV. The proposed specific aims will answer critical questions about the best strategies for identifying and treating HCV and HIV/HCV co-infection. The project will develop a durable platform poised to be the premier tool for rapidly conducting rigorous analyses of the comparative-effectiveness and cost-effectiveness of strategies for improving HCV and HIV/HCV care in the new era of effective HCV therapy.

Public Health Relevance

Hepatitis C Virus-related (HCV) liver disease is a leading cause of mortality in HIV-infected people in the U.S. and a particular health threat for vulnerable populations, such as current and former drug users. The Institute of Medicine recently recommended expanding screening for HCV and improving the availability of HCV treatment in vulnerable populations. This project uses simulation modeling methods to generate the evidence needed to establish best practices for identifying HCV infection and managing HIV/HCV co-infection.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA031059-03
Application #
8662217
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Kahana, Shoshana Y
Project Start
2012-06-15
Project End
2016-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Boston Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02118
Freiman, J Morgan; Tran, Trang M; Schumacher, Samuel G et al. (2016) Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med 165:345-55
Carey, Katelyn J; Huang, Wei; Linas, Benjamin P et al. (2016) Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat 66:54-9
Linas, Benjamin P (2016) Understanding Cost and Value in Hepatitis C Therapy. Top Antivir Med 24:93-97
Young, K L; Huang, W; Horsburgh, C R et al. (2016) Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. J Viral Hepat 23:274-81
Pho, M T; Jensen, D M; Meltzer, D O et al. (2015) Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat 22:630-8
Linas, Benjamin P; Barter, Devra M; Morgan, Jake R et al. (2015) The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 162:619-29
Linas, Benjamin P (2015) Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries. J Infect Dis 212:513-5
Schackman, Bruce R; Leff, Jared A; Barter, Devra M et al. (2015) Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110:129-43
Taylor, Lynn E; Foont, Julie A; DeLong, Allison K et al. (2014) The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. AIDS Patient Care STDS 28:4-9
Freiman, J Morgan; Huang, Wei; White, Laura F et al. (2014) Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. Clin Infect Dis 59:1686-93

Showing the most recent 10 out of 20 publications